Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Jun 13, 2024

BUY
$0.3 - $0.56 $900 - $1,680
3,000 Added 8.38%
38,800 $14,000
Q3 2022

Nov 10, 2022

SELL
$0.48 - $1.11 $714 - $1,651
-1,488 Reduced 3.99%
35,800 $18,000
Q2 2022

Aug 11, 2022

SELL
$0.41 - $0.88 $129 - $277
-315 Reduced 0.84%
37,288 $22,000
Q1 2022

May 12, 2022

BUY
$0.74 - $1.22 $1,334 - $2,199
1,803 Added 5.04%
37,603 $30,000
Q4 2021

Feb 11, 2022

SELL
$1.13 - $2.31 $8,194 - $16,752
-7,252 Reduced 16.84%
35,800 $44,000
Q3 2021

Nov 12, 2021

BUY
$1.83 - $3.18 $78,785 - $136,905
43,052 New
43,052 $102,000

Others Institutions Holding CYBN

About CYBIN INC.


  • Ticker CYBN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 166,120,000
  • Market Cap $2.07B
  • Description
  • Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...
More about CYBN
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.